Semaglutide SOUL trial: study classification corrected from Phase 1–2 to Phase 3
What WPF says today
WPF's semaglutide profile now classifies the SOUL trial (registry NCT03914326; N Engl J Med 2025, PMID 40162642), an oral semaglutide cardiovascular outcomes trial in 9,651 people with type 2 diabetes and cardiovascular or kidney disease, as Phase 3 human evidence. It had been labelled Phase 1–2. The stored evidence-strength grade is unchanged at A (86, provisional), and the trial's results are unchanged.
Semaglutide profile: source record for PMID 40162642 (SOUL) (52202c7e51446e0b3fd46d4144cf9239)
What this change did to the conclusion
Study classification corrected. WPF's record labelled a study with the wrong study type or phase. Only that label changed: the trial's results, the evidence-strength grade WPF had stored and every verdict stayed as they were.
Verdict: unchanged (Not a claim-check change: no claim verdict was involved)
The correction changes the study classification of one source record, from Phase 1–2 to Phase 3. It does not change the stored evidence-strength grade (A, 86, provisional), the grade's rationale, any trial result or any claim-check verdict. The grade is an automated baseline that the pipeline which produced it will recompute later for the corrected tier; if that changes the number, it will be recorded as its own change.
Before and after
Earlier: (the profile record before 2026-11-16)
- Evidence tier: "Phase 1-2 human evidence" (stored value phase_1_2) for the SOUL publication, PMID 40162642.
- Evidence-strength grade: A, 86 out of 100, provisional (an automated baseline), with its rationale.
Now: (the profile record from 2026-11-16)
- Evidence tier: "Phase 3 human evidence" (stored value phase_3) for the same publication.
- Evidence-strength grade: still A, 86 out of 100, provisional, with the same rationale. The grade was not recomputed by this correction.
- The trial's results, the publication and the registry record are exactly as they were.
Exact records. Earlier: no separate public address is recorded for the earlier snapshot (it is retained, see the Correction Log entry). Updated: Semaglutide profile (current) · Scholarly export, semaglutide (current).
Where to verify it
- ClinicalTrials.gov NCT03914326: API v2, protocolSection.designModule.phases = [PHASE3]; designModule.enrollmentInfo.count = 9651 (actual)
- PubMed, PMID 40162642 (N Engl J Med 2025;392(20):2001-2012): Publication types: Randomized Controlled Trial, Multicenter Study. DOI 10.1056/NEJMoa2501006
- WPF semaglutide profile: The source card for PMID 40162642: Evidence tier "Phase 3 human evidence"; Evidence strength A · 86/100 · Provisional
- WPF scholarly export, semaglutide: evidence[] item with pubmedId 40162642: evidenceTier = phase_3; extractionPayload.sourceStrength = grade A, score 86, provisional true
Dates
- Registry record first posted (NCT03914326):
- Publication (PubMed print date, N Engl J Med 392(20)): . PubMed entered the record on 2025-03-31.
- Registry results first posted (NCT03914326):
- WPF verified the source for this change:
- WPF published the corrected version:
Limits and review status
- Earlier public snapshots of the profile are retained (Correction Log), but no separate public address for the older snapshot is recorded here; the earlier wording above is the entry's own description of what the record said.
- The A (86) grade is a provisional automated baseline computed for the earlier tier. This correction does not claim it is the right number for a Phase 3 trial, only that it was not changed.
- This is a classification correction. It says nothing about whether oral semaglutide works, for whom, or how safe it is.
Review status: AI-assisted source verification. Documented human review: none recorded. This is not scientific review and not attribution to a named reviewer.
Formal record: Correction Log entry.
Cite this change
World Peptide Foundation. "Semaglutide SOUL trial: study classification corrected from Phase 1–2 to Phase 3". Change record semaglutide-soul-phase-3-classification, published 2026-11-16; WPF verified the source on 2026-11-16. Affected records: 52202c7e51446e0b3fd46d4144cf9239. Change type: Study classification corrected. Before and after: (the profile record before 2026-11-16) to (the profile record from 2026-11-16). AI-assisted source verification; documented human review: none recorded. https://www.worldpeptidefoundation.org/research/changes/semaglutide-soul-phase-3-classification